This is a preview of subscription content, log in via an institution to check access.
References
Clinical and Laboratory Standards Institute (CLSI). Quality management system: a model for laboratory services; approved guideline 4th edn. (Document no. GP26–A4, Vol. 31, No. 15) (Clinical and Laboratory Standards Institute, 2011).
Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988 (Part 493) 1443–1495 (US Department of Health and Human Services, 1988).
International Organization for Standardization. ISO 15189 Medical laboratories—Particular requirements for quality and competence (International Organization for Standardization, 2007).
Clinical and Laboratory Standards Institute (CLSI). Molecular Methods for Clinical Genetics and Oncology Testing; Approved Guideline-Third Edition CLSI (Document MM01-A3, Vol 32, No. 7) (Clinical and Laboratory Standards Institute, 2012).
Durbin, R.M. et al. Nature 467, 1061–1073 (2010).
Acknowledgements
The authors thank E. Mansfield, N. Aziz, P. Keller, J. Kaufman, S. Ghosh, R. Leach, J. Robinson, A. Felsenfeld, M. Salit and E. Highsmith for their help and support. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC or the US Agency for Toxic Substances and Disease Registry. The identification of certain commercial equipment, instruments or materials in this document does not imply recommendation or endorsement by the US National Institute of Standards and Technology, nor does it imply that the products identified are necessarily the best available for the purpose. The research was supported in part by an appointment to A.S.G. to the Research Participation Program at the CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.P.D. works at the Medical College of Wisconsin; T.H. works at Illumina; E.L. works at University of Utah/ARUP Laboratories, has research grants from NIH/NICHD and NHGRI and receives consulting fees from Novartis and Complete Genomics; E.L.H.C. worked at Emory University School of Medicine and now works at Baylor College of Medicine; J.G.C. works at GeneDX; D.H.F. works at Sequenom; M.R.F. works at and owns stock in Life Technologies; C.J.L. works at Softgenetics; M.G.R. works at and owns stock options/bonds and has ownership in Omicia; B.B.S. works at Life Sciences (Roche); J.M.Y. works at and owns stock in Illumina.
Supplementary information
Supplementary Text and Figures
Supplementary Guidelines, Supplementary Figure 1 and Supplementary Tables 1–4 (PDF 490 kb)
Rights and permissions
About this article
Cite this article
Gargis, A., Kalman, L., Berry, M. et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol 30, 1033–1036 (2012). https://doi.org/10.1038/nbt.2403
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2403
- Springer Nature America, Inc.
This article is cited by
-
The Quartet Data Portal: integration of community-wide resources for multiomics quality control
Genome Biology (2023)
-
Mastering DNA chromatogram analysis in Sanger sequencing for reliable clinical analysis
Journal of Genetic Engineering and Biotechnology (2023)
-
Developing an effective quality evaluation strategy of next-generation sequencing for accurate detecting non-small cell lung cancer samples with variable characteristics: a real-world clinical practice
Journal of Cancer Research and Clinical Oncology (2023)
-
SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP)
Virchows Archiv (2023)
-
Whole-genome sequencing as an investigational device for return of hereditary disease risk and pharmacogenomic results as part of the All of Us Research Program
Genome Medicine (2022)